Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

被引：0
|
作者：
Yi, Shuhua [1 ,2 ,3 ]
Jin, Jie [4 ]
Zhou, Keshu [5 ]
Zhu, Huayuan [6 ]
Ma, Kate [7 ]
Jiang, Rili [8 ]
Wang, Weige [8 ]
Zhang, Bin [9 ]
Qiu, Lugui [1 ,2 ,3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[3] Tianjin Inst Hlth Sci, Tianjin, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[6] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China
[7] Beijing InnoCare Pharm Tech Co Ltd, Beijing, Peoples R China
[8] Beijing InnoCare Pharm Tech Co Ltd, Shanghai, Peoples R China
[9] InnoCare Pharma Ltd, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Preliminary safety, efficacy, and pharmacodynamics of a highly selective P130 inhibitor, INCB050465, in patients with previously treated B -cell malignancies
    Forero-Torres, Andres
    Wertheim, Michael S.
    Phillips, Tycel J.
    Gutierrez, Martin E.
    Edenfield, William J.
    Yeleswaram, Swamy
    Bleam, Maureen
    Zhou, Li
    Pulini, Jennifer H.
    Faivre, Thea
    Miao, Harry
    Spear, Matt
    Ramchandren, Rod
    CANCER RESEARCH, 2016, 76
  • [22] A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
    Li, Caixia
    Wei, Jia
    Zhou, Keshu
    Liu, Peng
    Huang, He
    Li, Fei
    Cai, Qingqing
    Dong, Yujun
    Yang, Shenmiao
    Zhou, Hui
    Zhang, Xinyou
    Zhang, Lu
    Shi, Zaixing
    Liang, Zhiyu
    Wu, Binghao
    Wu, Depei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] EL-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Abrisqueta, Pau
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S375 - S375
  • [24] Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
    Dreyling, Martin
    Santoro, Armando
    Mollica, Luigina
    Leppa, Sirpa
    Follows, George A.
    Lenz, Georg
    Kim, Won Seog
    Nagler, Arnon
    Panayiotidis, Panayiotis
    Demeter, Judit
    Ozcan, Muhit
    Kosinova, Marina
    Bouabdallah, Krimo
    Morschhauser, Franck
    Stevens, Don
    Trevarthen, David
    Rodrigues, Liana
    Hiemeyer, Florian
    Wang, MingLu
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Zinzani, Pier Luigi
    BLOOD, 2018, 132
  • [25] Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2.
    Allen, Joshua M.
    Mendez, Ana Lucia Ruano
    Rybicki, Lisa A.
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad L.
    Smith, Mitchell Reed
    Hsi, Eric D.
    Hill, Brian Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study
    Karol, Seth E.
    Cooper, Todd M.
    Bittencourt, Henrique
    Gore, Lia
    O'Brien, Maureen M.
    Fraser, Christopher
    Gambart, Marion
    Cario, Gunnar
    Zwaan, Christian Michel
    Bourquin, Jean-Pierre
    Loh, Mignon L.
    Caron, Hubert
    Prine, Betty
    Salem, Ahmed Hamed
    Unnebrink, Kristina
    Tong, Bo
    Palenski, Tammy
    Place, Andrew E.
    BLOOD, 2019, 134
  • [27] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi Luigi
    BLOOD, 2021, 138
  • [28] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
  • [29] Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Coombs, Catherine Callaghan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 6 - 7
  • [30] The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
    Fowler, Nathan
    Sharman, Jeff Porte
    Smith, Sonali M.
    Boyd, Thomas
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Buggy, Joseph
    Loury, David
    Hamdy, Ahmed
    Advani, Ranjana
    BLOOD, 2010, 116 (21) : 425 - 425
12345